Vestal Point Capital’s Voyager Therapeutics VYGR Stock Holding History

Vestal Point Capital’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.19M	Sell	2,625,000 -377,936	-13%	-$1.43M	0.21%	55
2026 Q1	$11.6M	Buy	3,002,936 +1,527,936	+104%	+$6.02M	0.32%	62
2025 Q4	$5.8M	Hold	1,475,000	–	–	0.2%	59
2025 Q3	$6.89M	Hold	1,475,000	–	–	0.31%	57
2025 Q2	$4.59M	Buy	1,475,000 +225,582	+18%	+$728K	0.24%	53
2025 Q1	$4.22M	Buy	1,249,418 +19,418	+2%	+$90.7K	0.3%	46
2024 Q4	$6.97M	Buy	1,230,000 +740,000	+151%	+$4.77M	0.41%	49
2024 Q3	$2.87M	Sell	490,000 -110,000	-18%	-$800K	0.22%	59
2024 Q2	$4.75M	Hold	600,000	–	–	0.35%	45
2024 Q1	$5.59M	Buy	+600,000	New	+$5.07M	0.46%	42

Other funds holding VYGR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vestal Point Capital's VYGR Position: Q2 2026 in Review

Vestal Point Capital reduced its Voyager Therapeutics (VYGR) stake by 13% in Q2 2026, selling an estimated $1.43M and leaving 2,625,000 shares worth $9.19M. The position accounts for 0.21% of the portfolio, ranked #55.

Vestal Point Capital first reported a position in VYGR in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.6M in Q1 2026. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

Vestal Point Capital held 2,625,000 shares of Voyager Therapeutics worth $9.19M as of Q2 2026.
Vestal Point Capital sold 377,936 Voyager Therapeutics shares in Q2 2026, an estimated $1.43M.
Voyager Therapeutics made up 0.21% of Vestal Point Capital's portfolio in Q2 2026, its #55 holding.
Vestal Point Capital first reported a position in Voyager Therapeutics in Q1 2024 and has held it in 10 quarters since.
Vestal Point Capital's Voyager Therapeutics position peaked at $11.6M in Q1 2026.
136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.